JWS Consulting is a division of Johnson Winter & Slattery providing commercial consulting services.
We are engaged by major Australian and international corporations as legal counsel on their business activities, disputes and most challenging matters.
Our news and media coverage including major transaction announcements, practitioner appointments and team expansions.
We support a number of community initiatives and not for profit organisations across Australia through pro bono legal work and charitable donations.
We support a number of organisations through sponsorships.
Over the last 15 years, ASX has become an attractive alternative market for US lifescience companies, and more specifically, medical device companies, with the opportunity to raise early-stage capital in the public markets. Raising comparable public funds in the much larger and competitive US market has tended to be challenging for companies still at the development stage or even in the early commercialisation stage, whereas investors on ASX have shown to be more receptive to providing early-stage capital. This risk appetite is a function of our market’s experience with speculative resources stocks, and also the lack of a deep venture capital financing market in Australia.
ASX has implemented a number of measures to make ASX a more accessible market for US companies. These measures started back in 2000 when ASX sought, and was granted, a no-action letter from the US Securities and Exchange Commission (SEC) for initial public offerings of non-reporting US companies on ASX that are made in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933. The effect of this letter has facilitated so-called “Reg S offerings” in Australia by modifying some of the relevant requirements. The key conditions include excluding US persons from participating in the public offering (though US persons can still participate in the overall offering via a separate private placement), and flagging the securities as Foreign Ownership Restriction (FOR) securities for 12 months so as to inform the market on the prohibition on US persons acquiring the securities.
ASX has also become receptive to granting waivers from certain ASX listing rules requirements which are inconsistent with US laws or practices, or create unfair burdens for US issuers. Waivers are commonly granted to US issuers to:
If a listing on a major US market, such as the Nasdaq, is a future goal for a US issuer, an existing listing on ASX poses no hindrance to entry into the US markets. HeartWare International, Inc. successfully listed on Nasdaq in early 2009, as did Unilife Corporation (2010), and Sunshine Heart, Inc. (2013). Each of these companies started their ‘public life’ on the ASX.
Although foreign companies typically cannot trade their shares electronically on ASX, but must rather issue CHESS Depositary Interests (CDIs) representing the underlying shares – the flexibility of having CDIs trade on ASX can actually assist US issuers to meet the criteria for a listing on Nasdaq. Specifically, Nasdaq has a minimum listing bid price of US$4.00 per share, however CDIs can trade at an exchange ratio to shares of the issuer’s choosing. For example, Heartware adopted a CDI to share ratio of 35:1, Unilife adopted a 6:1 ratio (recently changed to a 60:1 ratio) and Sunshine Heart adopted a 200:1 ratio. This also means that US issuers can maintain a trading price on ASX that is customary for lifescience stocks, whilst trading its shares at a higher price on Nasdaq.
James and Clare have acted and continue to act for a number of US issuers, including HeartWare Limited (ASX: HWI), Peplin, Inc. (ASX:PLI), Sunshine Heart, Inc. (ASX:SHI), Osprey Medical, Inc. (ASX:OSP) and AirXpanders, Inc. (ASX:AXP). JWS is currently advising other US issuers considering an Australian IPO and ASX-listing.